A Sensing Platform for Rapid at Home-Test of COVID-19

用于快速在家检测 COVID-19 的传感平台

• 批准号: 10158929
• 负责人: Dipanjan Pan
• 金额: $ 7.65万
• 依托单位: UNIVERSITY OF MARYLAND BALTIMORE COUNTY
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-08-15 至 2022-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10158929
• 关键词: 2019-nCoV; Affect; American; Amino Acids; Antisense Oligonucleotides; Biological; Biological Assay; Biosensing Techniques; Biosensor; Body Fluids; COVID-19; Calibration; Car Phone; Cessation of life; Chemicals; Chiroptera; Clinical; Color; Communicable Diseases; Communities; Coronavirus; Country; Data; Deposition; Detection; Diagnosis; European; Failure; Far East; Flu virus; Genes; Genetic; Genome; Health system; Home environment; Human; Individual; Infection; Lateral; Length; Measurement; Mediating; Membrane Glycoproteins; Modification; Nucleocapsid; Outcome; Output; Paper; Patients; Performance; Phosphoproteins; Polymerase Chain Reaction; RNA; Race; Reaction Time; Reporting; Reproducibility; Research Personnel; Reverse Transcription; Saliva; Sampling; Scientist; Sensitivity and Specificity; Specificity; Sulfhydryl Compounds; Surface Plasmon Resonance; Swab; Symptoms; Techniques; Testing; Time; Transportation; United States; Variant; Viola; Virus; accurate diagnosis; base; chest computed tomography; cost; cost effective; design; disease diagnosis; env Gene Products; genetic variant; nanoGold; nanoparticle; novel strategies; plasmonics; point of care; sample collection; screening; seasonal influenza; sensor; software development; viral RNA; viral genomics; virus genetics; whole genome

ABSTRACT Since the first case of COVID-19 was reported in the United States (U.S.) on January 21st, 2020, it has already been ascertained to affect >900K active cases with >50K deaths. Currently, COVID-19 is being diagnosed primarily by three techniques, i.e. reverse-transcription polymerase chain reaction (RT-PCR), gene sequencing and chest computed tomography (CT). However, limitations of sample collection and transportation, as well as kit performance with inadequate access to advanced instrumental techniques, often cannot report COVID-19 at its initial presentation leading to the spread of this infectious disease to a wider community. Moreover, researchers found at least three central variants, distinguishable by amino acid changes, among 160 different complete human SARS-CoV-2 genome sequences. This limits the universal applicability of the currently available commercial COVID-19 kits. In this proposal we present a novel approach for screening of active COVID-19 cases with a paper based lateral flow assay mediated colorimetric POC biosensor that would be able to detect the SARS-CoV-2 gene sequence using specifically designed antisense oligonucleotides (ASO). This unique approach for selective sensing of SARS-CoV-2 eliminates the possibility of misinterpretation arisen due to the genomic variants of SARS-CoV-2 which is the most concerning limitation of the current COVID-19 sensing kits.

摘要 自美国（美国）报告首例COVID-19病例以来，本集团已于二零二零年十二月三十一日（星期四）开始对COVID-19进行评估。2020年1月21日， 已经确定影响> 900 K活动病例，其中> 50 K死亡。目前，COVID-19 主要通过三种技术进行诊断，即逆转录聚合酶链 RT-PCR、基因测序和胸部计算机断层扫描（CT）。然而，局限性 样本采集和运输的效率以及试剂盒的性能， 先进的仪器技术，往往不能报告COVID-19在其最初的介绍， 这种传染病传播到更广泛的社区。此外，研究人员发现，至少 在160个不同的完整人类基因组中， SARS-CoV-2基因组序列。这限制了目前可用的 商业COVID-19试剂盒。在这个建议中，我们提出了一种新的方法来筛选活性 COVID-19病例使用基于纸的侧流测定介导的比色POC生物传感器， 将能够检测SARS-CoV-2基因序列使用专门设计的反义核酸， 寡核苷酸（阿索）。这种选择性检测SARS-CoV-2的独特方法消除了 由于SARS-CoV-2的基因组变异，可能会出现误解， 关于当前COVID-19传感试剂盒的局限性。